ISSUE @ A GLANCE

Lipids and lipid lowering: current management with statins and PCSK9 inhibitors
T. F. Lüscher 1117

CardioPulse

Paul Hugenholtz MD at 90
J. Ozkan 1121

Carlos E Ruiz
M. Nicholls 1123

Neglected Populations, Neglected Diseases
J. Panhuis 1124

German Cardiac Society: Its History
G. Arnold and J.D. Schipke 1127

CURRENT OPINION

Lipids
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

SPECIAL ARTICLE

EACPR/AHA scientific statement
2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations
M. Guazzi, R. Arena, M. Halle, M.F. Piepoli, J. Myers, and C.J. Lavie 1144

CLINICAL RESEARCH

Lipids
Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol
G.R. Thompson, D.J. Blom, A.D. Marais, M. Seed, G.J. Pilcher, and F.J. Raal 1162

Editorial
Homozygous familial hypercholesterolaemia: light at the end of the tunnel
R.M. Stoekenbroek, G. Kees Hovingh, and J.J.P. Kastelein 1169
META-ANALYSIS

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intervention</th>
<th>Control</th>
<th>RR (95% CI)</th>
<th>I²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin vs. no statin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>2656/26447</td>
<td>3107/26427</td>
<td>0.85 (0.78 to 0.92)</td>
<td>48%</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>1434/23596</td>
<td>1825/23549</td>
<td>0.79 (0.73 to 0.84)</td>
<td>3%</td>
</tr>
<tr>
<td>More statin vs. less statin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>1706220505</td>
<td>1807220458</td>
<td>0.95 (0.87 to 1.03)</td>
<td>25%</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>88313411</td>
<td>91913389</td>
<td>0.96 (0.90 to 1.02)</td>
<td>23%</td>
</tr>
<tr>
<td>Non-statin vs. placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>172129726</td>
<td>172629844</td>
<td>0.99 (0.89 to 1.09)</td>
<td>31%</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>81628173</td>
<td>81228156</td>
<td>1.00 (0.91 to 1.09)</td>
<td>0%</td>
</tr>
</tbody>
</table>

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

CLINICAL RESEARCH

Lipids
U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies
C.M. Madsen, A. Varbo, A. Tybjerg-Hansen, R. Frikke-Schmidt, and B.G. Nordestgaard

Editorial
High-density lipoprotein (HDL) and infections: a versatile culprit
T. Speer and S. Zewinger

BASIC SCIENCE

Prevention and epidemiology
Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis

Editorial
HDL biogenesis revisited: how desmocollin-1 could sabotage reverse cholesterol transport in the arterial wall
D. Rhainds, M.R. Brodeur, Y. Rautureau, and J.-C. Tardif

CARDIOVASCULAR FLASHLIGHTS

Asymptomatic dissection of a giant aorta ascendens aneurysm in Turner syndrome
P. Dobrowolski, A. Klisiewicz, I. Michalowska, M. Kuśmierczyk, and P. Hoffman

Double-orifice Barlow’s mitral valve
## CORRIGENDA

Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction 1180
Corrigendum to: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 1206

---

For the podcast associated with this article, please visit [https://academic.oup.com/eurheartj/pages/Podcasts](https://academic.oup.com/eurheartj/pages/Podcasts)